{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T14:35:34Z","timestamp":1790260534240,"version":"4.1.0"},"reference-count":271,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2018,7,27]],"date-time":"2018-07-27T00:00:00Z","timestamp":1532649600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute of Health Research","doi-asserted-by":"crossref","award":["DRF-2016-09-065"],"award-info":[{"award-number":["DRF-2016-09-065"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,1,1]]},"abstract":"Abstract<\/jats:title>\n Malignant pleural effusions (MPE) are a common pathology, treated by respiratory physicians and thoracic surgeons alike. In recent years, several well-designed randomized clinical trials have been published that have changed the landscape of MPE management. The European Respiratory Society (ERS) and the European Association for Cardio-Thoracic Surgery (EACTS) established a multidisciplinary collaboration of clinicians with expertise in the management of MPE with the aim of producing a comprehensive review of the scientific literature. Six areas of interest were identified, including the optimum management of symptomatic MPE, management of trapped lung in MPE, management of loculated MPE, prognostic factors in MPE, whether there is a role for oncological therapies prior to intervention for MPE and whether a histological diagnosis is always required in MPE. The literature revealed that talc pleurodesis and indwelling pleural catheters effectively manage the symptoms of MPE. There was limited evidence regarding the management of trapped lung or loculated MPE. The LENT score was identified as a validated tool for predicting survival in MPE, with Brims' prognostic score demonstrating utility in mesothelioma prognostication. There was no evidence to support the use of oncological therapies as an alternative to MPE drainage, and the literature supported the use of tissue biopsy as the gold standard for diagnosis and treatment planning.<\/jats:p>\n Management options for malignant pleural effusions have advanced over the past decade, with high-quality randomized trial evidence informing practice in many areas. However, uncertainties remain and further research is required http:\/\/ow.ly\/rNt730jOxOS<\/jats:p>","DOI":"10.1093\/ejcts\/ezy258","type":"journal-article","created":{"date-parts":[[2018,6,25]],"date-time":"2018-06-25T15:13:16Z","timestamp":1529939596000},"page":"116-132","source":"Crossref","is-referenced-by-count":100,"title":["ERS\/EACTS statement on the management of malignant pleural effusions"],"prefix":"10.1093","volume":"55","author":[{"given":"Anna C","family":"Bibby","sequence":"first","affiliation":[{"name":"Academic Respiratory Unit, University of Bristol Medical School Translational Health Sciences, Bristol, UK"},{"name":"North Bristol Lung Centre, North Bristol NHS Trust, Bristol, UK"},{"name":"North Bristol Lung Centre, North Bristol NHS Trust, Bristol, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Dorn","sequence":"additional","affiliation":[{"name":"Division of Thoracic Surgery, University Hospital Bern, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Psallidas","sequence":"additional","affiliation":[{"name":"Oxford Respiratory Trials Unit, University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose M","family":"Porcel","sequence":"additional","affiliation":[{"name":"Pleural Medicine Unit, Arnau de Vilanova University Hospital, IRB Lleida, Lleida, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julius","family":"Janssen","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Diseases, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marios","family":"Froudarakis","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Medical School of Alexandroupolis, Democritus University of Thrace, Alexandroupolis, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dragan","family":"Subotic","sequence":"additional","affiliation":[{"name":"Clinic for Thoracic Surgery, Clinical Center of Serbia, Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillippe","family":"Astoul","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology, Pleural Diseases and Interventional Pulmonology, Hospital North Aix-Marseille University, Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Licht","sequence":"additional","affiliation":[{"name":"Department of Cardiothoracic Surgery, Odense University Hospital, Odense, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph","family":"Schmid","sequence":"additional","affiliation":[{"name":"Division of Thoracic Surgery, University Hospital Bern, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Scherpereel","sequence":"additional","affiliation":[{"name":"Pulmonary and Thoracic Oncology Department, Hospital of the University (CHU) of Lille, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Najib M","family":"Rahman","sequence":"additional","affiliation":[{"name":"Oxford Respiratory Trials Unit, University of Oxford, Oxford, UK"},{"name":"Oxford Centre for Respiratory Medicine, University Hospitals, NHS Foundation Trust, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick A","family":"Maskell","sequence":"additional","affiliation":[{"name":"Academic Respiratory Unit, University of Bristol Medical School Translational Health Sciences, Bristol, UK"},{"name":"North Bristol Lung Centre, North Bristol NHS Trust, Bristol, UK"},{"name":"Task force chairperson"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Cardillo","sequence":"additional","affiliation":[{"name":"Task force chairperson"},{"name":"Department of Thoracic Surgery, Carlo Forlanini Hospital, Azienda Ospedaliera San Camillo Forlanini, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,7,27]]},"reference":[{"issue":"5","key":"2025110203545358500_ezy258-B1","first-page":"CD010529","article-title":"Interventions for the management of malignant pleural effusions: a network meta-analysis","author":"Clive","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"Suppl. 2","key":"2025110203545358500_ezy258-B2","first-page":"ii32","article-title":"Management of a malignant pleural effusion: British Thoracic Society pleural disease guideline 2010","volume":"65","author":"Roberts","year":"2010","journal-title":"Thorax"},{"key":"2025110203545358500_ezy258-B3","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1001\/jama.2012.5535","article-title":"Effect of an indwelling pleural catheter vs chest tube and talc pleurodesis for relieving dyspnea in patients with malignant pleural effusion: the TIME2 randomized controlled trial","volume":"307","author":"Davies","year":"2012","journal-title":"JAMA"},{"key":"2025110203545358500_ezy258-B4","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1001\/jama.2015.16840","article-title":"Effect of opioids vs NSAIDs and larger vs smaller chest tube size on pain control and pleurodesis efficacy among patients with malignant pleural effusion: the TIME1 randomized clinical trial","volume":"314","author":"Rahman","year":"2015","journal-title":"JAMA"},{"key":"2025110203545358500_ezy258-B5","first-page":"S2","article-title":"A multi-centre randomised controlled trial of video assisted thoracoscopic pleurectomy versus talc pleurodesis in malignant pleural mesothelioma","volume":"8","author":"Rintoul","year":"2013","journal-title":"J Thorac Oncol"},{"key":"2025110203545358500_ezy258-B6","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1093\/icvts\/ivv182","article-title":"Is silver nitrate an effective means of pleurodesis?","volume":"21","author":"Bucknor","year":"2015","journal-title":"Interact CardioVasc Thorac Surg"},{"key":"2025110203545358500_ezy258-B7","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1378\/chest.128.2.684","article-title":"Prospective randomized trial of silver nitrate vs talc slurry in pleurodesis for symptomatic malignant pleural effusions","volume":"128","author":"da Silveira Paschoalini","year":"2005","journal-title":"Chest"},{"key":"2025110203545358500_ezy258-B8","doi-asserted-by":"crossref","first-page":"295890","DOI":"10.1155\/2013\/295890","article-title":"The effect of silver nitrate pleurodesis after a failed thoracoscopic talc poudrage","volume":"2013","author":"Menna","year":"2013","journal-title":"Biomed Res Int"},{"key":"2025110203545358500_ezy258-B9","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.ejcts.2005.12.025","article-title":"The evidence on the effectiveness of management for malignant pleural effusion: a systematic review","volume":"29","author":"Tan","year":"2006","journal-title":"Eur J Cardiothorac Surg"},{"key":"2025110203545358500_ezy258-B10","doi-asserted-by":"crossref","first-page":"254","DOI":"10.12688\/f1000research.5538.1","article-title":"Malignant pleural effusions and the role of talc poudrage and talc slurry: a systematic review and meta-analysis","volume":"3","author":"Mummadi","journal-title":"F1000Research 1000;"},{"key":"2025110203545358500_ezy258-B11","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1378\/chest.127.3.909","article-title":"Cooperative Groups Cancer and Leukemia Group B; Eastern Cooperative Oncology Group; North Central Cooperative Oncology Group; Radiation Therapy Oncology Group. Phase III intergroup study of talc poudrage vs talc slurry sclerosis for malignant pleural effusion","volume":"127","author":"Dresler","year":"2005","journal-title":"Chest"},{"key":"2025110203545358500_ezy258-B12","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/S0003-4975(96)00808-9","article-title":"Thoracoscopic talc insufflation versus talc slurry for symptomatic malignant pleural effusion","volume":"62","author":"Yim","year":"1996","journal-title":"Ann Thorac Surg"},{"key":"2025110203545358500_ezy258-B13","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1378\/chest.08-2448","article-title":"Is full postpleurodesis lung expansion a determinant of a successful outcome after talc pleurodesis?","volume":"136","author":"Terra","year":"2009","journal-title":"Chest"},{"key":"2025110203545358500_ezy258-B14","first-page":"131","article-title":"Palliative treatment of malignant pleural effusions by video-assisted thoracoscopic surgery","volume":"38","author":"Benk\u00f3","year":"1999","journal-title":"Acta Chir Hung"},{"key":"2025110203545358500_ezy258-B15","first-page":"463","article-title":"Talc pleurodesis: comparison of talc slurry instillation with thoracoscopic talc insufflation for malignant pleural effusions","volume":"11","author":"Debeljak","year":"2006","journal-title":"J BUON"},{"key":"2025110203545358500_ezy258-B16","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.ejcts.2006.10.002","article-title":"Talc poudrage versus talc slurry in the treatment of malignant pleural effusion. A prospective comparative study","volume":"30","author":"Stefani","year":"2006","journal-title":"Eur J Cardiothorac Surg"},{"key":"2025110203545358500_ezy258-B17","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1055\/s-2006-923931","article-title":"Malignant pleural effusion treatment outcomes: pleurodesis via video-assisted thoracic surgery (VATS) versus tube thoracostomy","volume":"54","author":"Luh","year":"2006","journal-title":"Thorac Cardiovasc Surg"},{"key":"2025110203545358500_ezy258-B18","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/0003-4975(95)01060-2","article-title":"Complications of video-assisted thoracic surgery: a five-year experience","volume":"61","author":"Jancovici","year":"1996","journal-title":"Ann Thorac Surg"},{"key":"2025110203545358500_ezy258-B19","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/S1010-7940(01)01130-7","article-title":"Long-term follow-up of video-assisted talc pleurodesis in malignant recurrent pleural effusions","volume":"21","author":"Cardillo","year":"2002","journal-title":"Eur J Cardiothorac Surg"},{"key":"2025110203545358500_ezy258-B20","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1055\/s-2007-1013677","article-title":"Videothoracoscopy in the diagnosis and treatment of malignant pleural mesothelioma with associated pleural effusions","volume":"45","author":"Canto","year":"1997","journal-title":"Thorac Cardiovasc Surg"},{"key":"2025110203545358500_ezy258-B21","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/j.athoracsur.2007.02.061","article-title":"Who gains most? A 10-year experience with 611 thoracoscopic talc pleurodeses","volume":"83","author":"Steger","year":"2007","journal-title":"Ann Thorac Surg"},{"key":"2025110203545358500_ezy258-B22","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(07)60708-9","article-title":"Safety of pleurodesis with talc poudrage in malignant pleural effusion: a prospective cohort study","volume":"369","author":"Janssen","year":"2007","journal-title":"Lancet"},{"key":"2025110203545358500_ezy258-B23","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1378\/chest.119.3.801","article-title":"Thoracoscopy talc poudrage: a 15-year experience","volume":"119","author":"de Campos","year":"2001","journal-title":"Chest"},{"key":"2025110203545358500_ezy258-B24","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/1749-8090-5-27","article-title":"Early and late morbidity and mortality and life expectancy following thoracoscopic talc insufflation for control of malignant pleural effusions: a review of 400 cases","volume":"5","author":"Barbetakis","year":"2010","journal-title":"J Cardiothorac Surg"},{"key":"2025110203545358500_ezy258-B25","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1378\/chest.110.6.1387","article-title":"Thoracoscopic talc poudrage pleurodesis for malignant effusions. A review of 360 cases","volume":"110","author":"Viallat","year":"1996","journal-title":"Chest"},{"key":"2025110203545358500_ezy258-B26","first-page":"9: 3","article-title":"Pleural effusions of malignant etiology: diagnostics,","author":"Koledin","year":"2001","journal-title":"treatment and quality of life. Arch Oncol"},{"key":"2025110203545358500_ezy258-B27","doi-asserted-by":"crossref","first-page":"326","DOI":"10.4103\/0970-2113.159551","article-title":"Clinico-pathological profile and course of malignant pleural effusion in a tertiary care teaching hospital in western U.P. with special reference to lung cancer","volume":"32","author":"Agrawal","year":"2015","journal-title":"Lung India"},{"key":"2025110203545358500_ezy258-B28","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s00464-005-0534-6","article-title":"Thoracoscopic palliative treatment of malignant pleural effusions: results in 273 patients","volume":"20","author":"Arapis","year":"2006","journal-title":"Surg Endosc"},{"key":"2025110203545358500_ezy258-B29","first-page":"324","article-title":"Thoracoscopic management of malignant pleural effusion","volume":"78","author":"Bal","year":"1993","journal-title":"Int Surg"},{"key":"2025110203545358500_ezy258-B30","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.hlc.2005.02.004","article-title":"Video-assisted thoracoscopic (VATS) pleurodesis for malignant effusion: an Australian teaching hospital's experience","volume":"14","author":"Trotter","year":"2005","journal-title":"Heart Lung Circ"},{"key":"2025110203545358500_ezy258-B31","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1378\/chest.104.5.1482","article-title":"Survival and talc pleurodesis in metastatic pleural carcinoma, revisited","volume":"104","author":"Sanchez-Armengol","year":"1993","journal-title":"Chest"},{"key":"2025110203545358500_ezy258-B32","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1089\/jpm.2011.0149","article-title":"Clinical outcomes and health-related quality of life after thoracoscopic talc pleurodesis","volume":"15","author":"Schniewind","year":"2012","journal-title":"J Palliat Med"},{"key":"2025110203545358500_ezy258-B33","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1378\/chest.128.3.1431","article-title":"Clinical efficacy and safety of thoracoscopic talc pleurodesis in malignant pleural effusions","volume":"128","author":"Kolschmann","year":"2005","journal-title":"Chest"},{"key":"2025110203545358500_ezy258-B34","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1016\/S0003-4975(01)02586-3","article-title":"Effective treatment of malignant pleural effusion by minimal invasive thoracic surgery: thoracoscopic talc pleurodesis and pleuroperitoneal shunts in 101 patients","volume":"71","author":"Schulze","year":"2001","journal-title":"Ann Thorac Surg"},{"key":"2025110203545358500_ezy258-B35","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S0954-6111(98)90315-8","article-title":"Treatment of malignant pleural effusion: pleurodesis using a small percutaneous catheter. A prospective randomized study","volume":"92","author":"Clementsen","year":"1998","journal-title":"Respir Med"},{"key":"2025110203545358500_ezy258-B36","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0169-5002(01)00475-5","article-title":"Distribution of talc suspension during treatment of malignant pleural effusion with talc pleurodesis","volume":"36","author":"Mager","year":"2002","journal-title":"Lung Cancer"},{"key":"2025110203545358500_ezy258-B37","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1159\/000342042","article-title":"Small particle-size talc is associated with poor outcome and increased inflammation in thoracoscopic pleurodesis","volume":"86","author":"Arellano-Orden","year":"2013","journal-title":"Respiration"},{"key":"2025110203545358500_ezy258-B38","doi-asserted-by":"crossref","first-page":"234","DOI":"10.5507\/bp.2014.038","article-title":"Predictive value of systemic and local inflammation parameters in talc pleurodesis assessment","volume":"159","author":"Habal","year":"2015","journal-title":"Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub"},{"key":"2025110203545358500_ezy258-B39","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1164\/ajrccm\/151.3_Pt_1.785","article-title":"Failure of talc pleurodesis is associated with increased pleural fibrinolysis","volume":"151","author":"Rodriguez-Panadero","year":"1995","journal-title":"Am J Respir Crit Care Med"},{"key":"2025110203545358500_ezy258-B40","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1007\/s00508-015-0716-8","article-title":"Talc pleurodesis improves survival of patients with malignant pleural effusions: case-control study","volume":"127","author":"Korsic","year":"2015","journal-title":"Wien Klin Wochenschr"},{"key":"2025110203545358500_ezy258-B41","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/1759-7714.12354","article-title":"Predictors of survival in patients who underwent video-assisted thoracic surgery talc pleurodesis for malignant pleural effusion","volume":"7","author":"Yoon","year":"2016","journal-title":"Thorac Cancer"},{"key":"2025110203545358500_ezy258-B42","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1080\/0961625X.1994.11665548","article-title":"Video-assisted thoracoscopic pleurectomy as therapy for recurring malignant pleural effusion","volume":"3","author":"Friedel","year":"1994","journal-title":"Minim Invasive Ther"},{"key":"2025110203545358500_ezy258-B43","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1378\/chest.107.5.1454","article-title":"Video-assisted thoracoscopic pleurectomy in the management of malignant pleural effusion","volume":"107","author":"Waller","year":"1995","journal-title":"Chest"},{"key":"2025110203545358500_ezy258-B44","first-page":"184","article-title":"Multimodality treatment including parietal pleurectomy as a possible therapeutic procedure for malignant pleural effusion","volume":"16","author":"Ohta","year":"2007","journal-title":"Surg Technol Int"},{"key":"2025110203545358500_ezy258-B45","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.ejcts.2004.03.010","article-title":"Impact of pleural effusion pH on the efficacy of thoracoscopic mechanical pleurodesis in patients with breast carcinoma","volume":"26","author":"Crnjac","year":"2004","journal-title":"Eur J Cardiothorac Surg"},{"key":"2025110203545358500_ezy258-B46","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1515\/raon-2015-0002","article-title":"Release of growth factors after mechanical and chemical pleurodesis for treatment of malignant pleural effusion: a randomized control study","volume":"49","author":"Hojski","year":"2015","journal-title":"Radiol Oncol"},{"key":"2025110203545358500_ezy258-B47","first-page":"1023","article-title":"Comparative study of video-assisted thoracoscopic surgery vs thoracic tube drainage in synthetic therapy for malignant pleural effusion secondary to non-small cell lung cancer","volume":"26","author":"Gu","year":"2006","journal-title":"Nan Fang Yi Ke Da Xue Xue Bao"},{"key":"2025110203545358500_ezy258-B48","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0003-4975(02)03599-3","article-title":"Early and late mortality after pleurodesis for malignant pleural effusion","volume":"74","author":"Bernard","year":"2002","journal-title":"Ann Thorac Surg"},{"key":"2025110203545358500_ezy258-B49","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1089\/jpm.2013.0617","article-title":"Quality of life and outcomes after nonintubated versus intubated video-thoracoscopic pleurodesis for malignant pleural effusion: comparison by a case-matched study","volume":"17","author":"Mineo","year":"2014","journal-title":"J Palliat Med"},{"key":"2025110203545358500_ezy258-B50","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1378\/chest.13-1908","article-title":"Quality-adjusted survival following treatment of malignant pleural effusions with indwelling pleural catheters","volume":"145","author":"Ost","year":"2014","journal-title":"Chest"},{"key":"2025110203545358500_ezy258-B51","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/j.athoracsur.2007.11.039","article-title":"Management of malignant pleural effusions using the Pleur(x) catheter","volume":"85","author":"Warren","year":"2008","journal-title":"Ann Thorac Surg"},{"key":"2025110203545358500_ezy258-B52","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1378\/chest.129.2.362","article-title":"Single-center experience with 250 tunnelled pleural catheter insertions for malignant pleural effusion","volume":"129","author":"Tremblay","year":"2006","journal-title":"Chest"},{"key":"2025110203545358500_ezy258-B53","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1159\/000342343","article-title":"The impact of tunneled pleural catheters on the quality of life of patients with malignant pleural effusions","volume":"85","author":"Sabur","year":"2013","journal-title":"Respiration"},{"key":"2025110203545358500_ezy258-B54","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1378\/chest.14-3119","article-title":"The use of indwelling tunneled pleural catheters for recurrent pleural effusions in patients with hematologic malignancies: a multicenter study","volume":"148","author":"Gilbert","year":"2015","journal-title":"Chest"},{"key":"2025110203545358500_ezy258-B55","doi-asserted-by":"crossref","first-page":"3482","DOI":"10.1245\/s10434-009-0691-2","article-title":"Ambulatory intercostal drainage for the management of malignant pleural effusion: a single center experience","volume":"16","author":"Bazerbashi","year":"2009","journal-title":"Ann Surg Oncol"},{"key":"2025110203545358500_ezy258-B56","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s11606-010-1472-0","article-title":"Efficacy and safety of tunneled pleural catheters in adults with malignant pleural effusions: a systematic review","volume":"26","author":"Van Meter","year":"2011","journal-title":"J Gen Intern Med"},{"key":"2025110203545358500_ezy258-B57","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1002\/(SICI)1097-0142(19991115)86:10<1992::AID-CNCR16>3.0.CO;2-M","article-title":"A randomized comparison of indwelling pleural catheter and doxycycline pleurodesis in the management of malignant pleural effusions","volume":"86","author":"Putnam","year":"1999","journal-title":"Cancer"},{"key":"2025110203545358500_ezy258-B58","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1001\/jama.2017.17426","article-title":"Effect of an indwelling pleural catheter vs talc pleurodesis on hospitalization days in patients with malignant pleural effusion: the AMPLE randomized clinical trial","volume":"318","author":"Thomas","year":"2017","journal-title":"JAMA"},{"key":"2025110203545358500_ezy258-B59","doi-asserted-by":"crossref","first-page":"975","DOI":"10.6004\/jnccn.2012.0102","article-title":"Optimal management of malignant pleural effusions (results of CALGB 30102)","volume":"10","author":"Demmy","year":"2012","journal-title":"J Natl Compr Canc Netw"},{"key":"2025110203545358500_ezy258-B60","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.athoracsur.2012.01.103","article-title":"Thoracoscopic talc versus tunneled pleural catheters for palliation of malignant pleural effusions","volume":"94","author":"Hunt","year":"2012","journal-title":"Ann Thorac Surg"},{"key":"2025110203545358500_ezy258-B61","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1378\/chest.11-2657","article-title":"Indwelling pleural catheters reduce inpatient days over pleurodesis for malignant pleural effusion","volume":"142","author":"Fysh","year":"2012","journal-title":"Chest"},{"key":"2025110203545358500_ezy258-B62","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1136\/bmjspcare-2012-000342","article-title":"A retrospective review of the palliative surgical management of malignant pleural effusions","volume":"4","author":"Bell","year":"2014","journal-title":"BMJ Support Palliat Care"},{"key":"2025110203545358500_ezy258-B63","doi-asserted-by":"crossref","first-page":"351","DOI":"10.12968\/ijpn.2016.22.7.351","article-title":"A prospective study of patient-centred outcomes in the management of malignant pleural effusions","volume":"22","author":"Walker","year":"2016","journal-title":"Int J Palliat Nurs"},{"key":"2025110203545358500_ezy258-B64","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1164\/rccm.201607-1404OC","article-title":"Randomized trial of pleural fluid drainage frequency in patients with malignant pleural effusions. The ASAP trial","volume":"195","author":"Wahidi","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"2025110203545358500_ezy258-B65","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1055\/s-2008-1039109","article-title":"Recurrent pleural effusion: who benefits from a tunneled pleural catheter?","volume":"57","author":"Schneider","year":"2009","journal-title":"Thorac Cardiovasc Surg"},{"key":"2025110203545358500_ezy258-B66","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/LBR.0000000000000186","article-title":"Pleuroscopic pleurodesis combined with tunneled pleural catheter for management of malignant pleural effusion: a prospective observational study","volume":"22","author":"Boujaoude","year":"2015","journal-title":"J Bronchology Interv Pulmonol"},{"key":"2025110203545358500_ezy258-B67","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1378\/chest.10-1868","article-title":"Rapid pleurodesis for malignant pleural effusions: a pilot study","volume":"139","author":"Reddy","year":"2011","journal-title":"Chest"},{"key":"2025110203545358500_ezy258-B68","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.athoracsur.2013.03.063","article-title":"A propensity-matched comparison of pleurodesis or tunneled pleural catheter in patients undergoing diagnostic thoracoscopy for malignancy","volume":"96","author":"Freeman","year":"2013","journal-title":"Ann Thorac Surg"},{"key":"2025110203545358500_ezy258-B69","doi-asserted-by":"crossref","first-page":"e007045","DOI":"10.1136\/bmjopen-2014-007045","article-title":"Evaluating the efficacy of thoracoscopy and talc poudrage versus pleurodesis using talc slurry (TAPPS trial): protocol of an open-label randomised controlled trial","volume":"4","author":"Bhatnagar","year":"2014","journal-title":"BMJ Open"},{"key":"2025110203545358500_ezy258-B70","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/S0140-6736(14)60418-9","article-title":"Efficacy and cost of video-assisted thoracoscopic partial pleurectomy versus talc pleurodesis in patients with malignant pleural mesothelioma (MesoVATS): an open-label, randomised, controlled trial","volume":"384","author":"Rintoul","year":"2014","journal-title":"Lancet"},{"key":"2025110203545358500_ezy258-B71","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3410\/M2-77","article-title":"The unexpandable lung","volume":"2","author":"Huggins","year":"2010","journal-title":"F1000 Med Rep"},{"key":"2025110203545358500_ezy258-B72","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/MAJ.0b013e31815f1a44","article-title":"Clinical implications of unexpandable lung due to pleural disease","volume":"335","author":"Doelken","year":"2008","journal-title":"Am J Med Sci"},{"key":"2025110203545358500_ezy258-B73","doi-asserted-by":"crossref","first-page":"768","DOI":"10.7326\/0003-4819-126-10-199705150-00003","article-title":"Elastance of the pleural space: a predictor for the outcome of pleurodesis in patients with malignant pleural effusion","volume":"126","author":"Lan","year":"1997","journal-title":"Ann Intern Med"},{"key":"2025110203545358500_ezy258-B74","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.ccm.2005.12.007","article-title":"Pleural manometry","volume":"27","author":"Huggins","year":"2006","journal-title":"Clin Chest Med"},{"key":"2025110203545358500_ezy258-B75","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1097\/MCP.0b013e3281214492","article-title":"Therapeutic thoracentesis: the role of ultrasound and pleural manometry","volume":"13","author":"Feller-Kopman","year":"2007","journal-title":"Curr Opin Pulm Med"},{"key":"2025110203545358500_ezy258-B76","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1097\/LBR.0b013e31829af168","article-title":"Pleural pressure swing and lung expansion after malignant pleural effusion drainage: the benefits of high-temporal resolution pleural manometry","volume":"20","author":"Boshuizen","year":"2013","journal-title":"J Bronchology Interv Pulmonol"},{"key":"2025110203545358500_ezy258-B77","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1378\/chest.129.6.1556","article-title":"The relationship of pleural pressure to symptom development during therapeutic thoracentesis","volume":"129","author":"Feller-Kopman","year":"2006","journal-title":"Chest"},{"key":"2025110203545358500_ezy258-B78","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1378\/chest.13-2876","article-title":"Novel use of pleural ultrasound can identify malignant entrapped lung prior to effusion drainage","volume":"146","author":"Salamonsen","year":"2014","journal-title":"Chest"},{"key":"2025110203545358500_ezy258-B79","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1510\/icvts.2010.254789","article-title":"What is the best treatment for malignant pleural effusions?","volume":"12","author":"Zahid","year":"2011","journal-title":"Interact CardioVasc Thorac Surg"},{"key":"2025110203545358500_ezy258-B80","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1378\/chest.119.6.1641","article-title":"Use of an implantable pleural catheter for trapped lung syndrome in patients with malignant pleural effusion","volume":"119","author":"Pien","year":"2001","journal-title":"Chest"},{"key":"2025110203545358500_ezy258-B81","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1177\/000313480306900304","article-title":"Use of an indwelling pleural catheter compared with thorascopic talc pleurodesis in the management of malignant pleural effusions","volume":"69","author":"Ohm","year":"2003","journal-title":"Am Surg"},{"key":"2025110203545358500_ezy258-B82","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1177\/021849230801600208","article-title":"Management of malignant pleural effusion associated with trapped lung syndrome","volume":"16","author":"Qureshi","year":"2008","journal-title":"Asian Cardiovasc Thorac Ann"},{"key":"2025110203545358500_ezy258-B83","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.lungcan.2005.05.016","article-title":"Management of recurrent malignant pleural effusions with a chronic indwelling pleural catheter","volume":"50","author":"van den Toorn","year":"2005","journal-title":"Lung Cancer"},{"key":"2025110203545358500_ezy258-B84","first-page":"1618","article-title":"[Chronic indwelling pleural catheter for malignant pleural effusion in 25 patients]","volume":"150","author":"Burgers","year":"2006","journal-title":"Ned Tijdschr Geneeskd"},{"key":"2025110203545358500_ezy258-B85","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1510\/icvts.2009.211516","article-title":"Malignant pleural effusion in the presence of trapped lung. Five-year experience of PleurX tunnelled catheters","volume":"9","author":"Efthymiou","year":"2009","journal-title":"Interact CardioVasc Thorac Surg"},{"key":"2025110203545358500_ezy258-B86","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1002\/1097-0142(19950201)75:3<801::AID-CNCR2820750309>3.0.CO;2-H","article-title":"Management of recurrent malignant pleural effusions: the complementary role of talc pleurodesis and pleuroperitoneal shunting","volume":"75","author":"Petrou","year":"1995","journal-title":"Cancer"},{"key":"2025110203545358500_ezy258-B87","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S1010-7940(00)00422-X","article-title":"The long-term morbidity of pleuroperitoneal shunts in the management of recurrent malignant effusions","volume":"18","author":"Genc","year":"2000","journal-title":"Eur J Cardiothorac Surg"},{"key":"2025110203545358500_ezy258-B88","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1111\/j.1445-2197.1995.tb00643.x","article-title":"Thoracoscopic management of pleural effusions revisited","volume":"65","author":"Yim","year":"1995","journal-title":"Aust N Z J Surg"},{"key":"2025110203545358500_ezy258-B89","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/S1556-0864(15)31612-9","article-title":"Intrapleural urokinase for the treatment of loculated malignant pleural effusions and trapped lungs in medically inoperable cancer patients","volume":"1","author":"Hsu","year":"2006","journal-title":"J Thorac Oncol"},{"key":"2025110203545358500_ezy258-B90","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/S0012-3692(15)50413-3","article-title":"Proinflammatory cytokines, transforming growth factor-\u03b21, and fibrinolytic enzymes in loculated and free-flowing pleural exudates","volume":"128","author":"Chung","year":"2005","journal-title":"Chest"},{"key":"2025110203545358500_ezy258-B91","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.ejso.2008.06.009","article-title":"Long-term indwelling pleural catheter (PleurX) for malignant pleural effusion unsuitable for talc pleurodesis","volume":"35","author":"Sioris","year":"2009","journal-title":"Eur J Surg Oncol"},{"key":"2025110203545358500_ezy258-B92","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1097\/JTO.0b013e318189f53d","article-title":"Diagnostic and prognostic implications of pleural adhesions in malignant effusions","volume":"3","author":"Bielsa","year":"2008","journal-title":"J Thorac Oncol"},{"key":"2025110203545358500_ezy258-B93","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1378\/chest.115.2.423","article-title":"Accuracy of CT for the detection of pleural adhesions: correlation with video-assisted thoracoscopic surgery","volume":"115","author":"Mason","year":"1999","journal-title":"Chest"},{"key":"2025110203545358500_ezy258-B94","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1093\/ejcts\/ezs144","article-title":"Accuracy of transthoracic ultrasound for the detection of pleural adhesions","volume":"42","author":"Cassanelli","year":"2012","journal-title":"Eur J Cardiothorac Surg"},{"key":"2025110203545358500_ezy258-B95","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1055\/s-0030-1270760","article-title":"Use of transthoracic ultrasound to predict pleural adhesions: a prospective blinded study","volume":"60","author":"Wei","year":"2012","journal-title":"Thorac Cardiovasc Surg"},{"key":"2025110203545358500_ezy258-B96","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1111\/j.1440-1843.2010.01768.x","article-title":"Thoracic ultrasound prior to medical thoracoscopy improves pleural access and predicts fibrous septation","volume":"15","author":"Medford","year":"2010","journal-title":"Respirology"},{"key":"2025110203545358500_ezy258-B97","first-page":"1124","article-title":"Value of chest ultrasonography versus decubitus roentgenography for thoracentesis","volume":"133","author":"Kohan","year":"1986","journal-title":"Am Rev Respir Dis"},{"issue":"Suppl. 2","key":"2025110203545358500_ezy258-B98","doi-asserted-by":"crossref","first-page":"i61","DOI":"10.1136\/thx.2010.137026","article-title":"Pleural procedures and thoracic ultrasound: British Thoracic Society pleural disease guideline 2010","volume":"65","author":"Havelock","year":"2010","journal-title":"Thorax"},{"key":"2025110203545358500_ezy258-B99","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1148\/radiology.169.1.3047789","article-title":"Thoracic empyema: management with image-guided catheter drainage","volume":"169","author":"Silverman","year":"1988","journal-title":"Radiology"},{"issue":"Suppl. 2","key":"2025110203545358500_ezy258-B100","first-page":"ii41","article-title":"Management of pleural infection in adults: British Thoracic Society Pleural Disease Guideline 2010","volume":"65","author":"Davies","year":"2010","journal-title":"Thorax"},{"key":"2025110203545358500_ezy258-B101","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1148\/radiology.151.2.6709904","article-title":"CT- and ultrasound-guided catheter drainage of empyemas after chest-tube failure","volume":"151","author":"VanSonnenberg","year":"1984","journal-title":"Radiology"},{"key":"2025110203545358500_ezy258-B102","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa1012740","article-title":"Intrapleural use of tissue plasminogen activator and DNase in pleural infection","volume":"365","author":"Rahman","year":"2011","journal-title":"N Engl J Med"},{"key":"2025110203545358500_ezy258-B103","first-page":"594","article-title":"Fibrinolysis of loculated pleural effusion in malignant mesothelioma","volume":"45","author":"Balamugesh","year":"2004","journal-title":"Singapore Med J"},{"key":"2025110203545358500_ezy258-B104","first-page":"59","article-title":"Intrapleural streptokinase in multiloculated malignant pleural effusion","volume":"46","author":"Dixit","year":"2004","journal-title":"Indian J Chest Dis Allied Sci"},{"key":"2025110203545358500_ezy258-B105","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.1056\/ENEJMicm020531","article-title":"Images in clinical medicine. Effect of intrapleural streptokinase on a loculated malignant pleural effusion","volume":"348","author":"Maskell","year":"2003","journal-title":"N Engl J Med"},{"key":"2025110203545358500_ezy258-B106","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1378\/chest.109.6.1514","article-title":"Intrapleural fibrinolysis with streptokinase as an adjunctive treatment in hemothorax and empyema: a multicenter trial","volume":"109","author":"Jerjes-Sanchez","year":"1996","journal-title":"Chest"},{"key":"2025110203545358500_ezy258-B107","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1378\/chest.115.3.729","article-title":"Intrapleural streptokinase in the management of malignant multiloculated pleural effusions","volume":"115","author":"Davies","year":"1999","journal-title":"Chest"},{"key":"2025110203545358500_ezy258-B108","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.athoracsur.2010.10.082","article-title":"Effectiveness and risks associated with intrapleural alteplase by means of tube thoracostomy","volume":"91","author":"Ben-Or","year":"2011","journal-title":"Ann Thorac Surg"},{"key":"2025110203545358500_ezy258-B109","doi-asserted-by":"crossref","first-page":"781","DOI":"10.2214\/ajr.173.3.10470923","article-title":"Using urokinase to treat malignant pleural effusions","volume":"173","author":"Gilkeson","year":"1999","journal-title":"AJR Am J Roentgenol"},{"key":"2025110203545358500_ezy258-B110","doi-asserted-by":"crossref","first-page":"e001887","DOI":"10.1136\/bmjopen-2012-001887","article-title":"Intrapleural fibrinolytic therapy (IPFT) in loculated pleural effusions\u2014analysis of predictors for failure of therapy and bleeding: a cohort study","volume":"3","author":"Abu-Daff","year":"2013","journal-title":"BMJ Open"},{"key":"2025110203545358500_ezy258-B111","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1177\/0218492311410874","article-title":"Streptokinase for malignant pleural effusions: a randomized controlled study","volume":"19","author":"Okur","year":"2011","journal-title":"Asian Cardiovasc Thorac Ann"},{"key":"2025110203545358500_ezy258-B112","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s12032-015-0612-0","article-title":"The palliative treatment with intrapleural streptokinase in patients with multiloculated malignant pleural effusion: a double-blind, placebo-controlled, randomized study","volume":"32","author":"Saydam","year":"2015","journal-title":"Med Oncol"},{"key":"2025110203545358500_ezy258-B113","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1164\/rccm.201704-0809OC","article-title":"Randomised controlled trial of urokinase versus placebo for non-draining malignant pleural effusion","volume":"197","author":"Mishra","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"2025110203545358500_ezy258-B114","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1378\/chest.14-2401","article-title":"Intrapleural fibrinolysis for the treatment of indwelling pleural catheter-related symptomatic loculations: a multicenter observational study","volume":"148","author":"Thomas","year":"2015","journal-title":"Chest"},{"key":"2025110203545358500_ezy258-B115","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1164\/ajrccm.162.5.ats8-00","article-title":"Management of malignant pleural effusions","volume":"162","author":"Antony","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"key":"2025110203545358500_ezy258-B116","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1378\/chest.117.1.79","article-title":"Pleural fluid pH as a predictor of survival for patients with malignant pleural effusions","volume":"117","author":"Heffner","year":"2000","journal-title":"Chest"},{"key":"2025110203545358500_ezy258-B117","first-page":"1233","article-title":"Relationship between 18 FDG PET-CT findings and the survival of 177 patients with malignant pleural mesothelioma","volume":"17","author":"Abakay","year":"2013","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"2025110203545358500_ezy258-B118","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s12890-015-0025-z","article-title":"Important prognostic factors for survival in patients with malignant pleural effusion","volume":"15","author":"Zamboni","year":"2015","journal-title":"BMC Pulm Med"},{"key":"2025110203545358500_ezy258-B119","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.ejim.2007.09.014","article-title":"Prognostic significance of pleural fluid data in patients with malignant effusion","volume":"19","author":"Bielsa","year":"2008","journal-title":"Eur J Intern Med"},{"key":"2025110203545358500_ezy258-B120","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1002\/1097-0142(19810415)47:8<2087::AID-CNCR2820470830>3.0.CO;2-9","article-title":"Pleural effusion in breast cancer: a review of 105 cases","volume":"47","author":"Fentiman","year":"1981","journal-title":"Cancer"},{"key":"2025110203545358500_ezy258-B121","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1159\/000356764","article-title":"Prognostic factors in patients presenting with pleural effusion revealing malignancy","volume":"87","author":"Anevlavis","year":"2014","journal-title":"Respiration"},{"key":"2025110203545358500_ezy258-B122","article-title":"American Joint Committee on Cancer","volume-title":"Staging manual","author":"Edge","year":"2009","edition":"7th Edn."},{"key":"2025110203545358500_ezy258-B123","article-title":"The IASLC Mesothelioma Staging Project: proposals for the M descriptors and for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for mesothelioma","author":"Rusch","journal-title":"J Thorac Oncol 2016; 11: 2112\u20132119."},{"key":"2025110203545358500_ezy258-B124","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/0959-8049(95)00664-8","article-title":"Karnofsky and ECOG performance status scoring in lung cancer: a prospective, longitudinal study of 536 patients from a single institution","volume":"32","author":"Buccheri","year":"1996","journal-title":"Eur J Cancer"},{"key":"2025110203545358500_ezy258-B125","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1081\/CNV-200032911","article-title":"Prediction of survival for advanced cancer patients by recursive partitioning analysis: role of Karnofsky performance status, quality of life, and symptom distress","volume":"22","author":"Hwang","year":"2004","journal-title":"Cancer Invest"},{"key":"2025110203545358500_ezy258-B126","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1378\/chest.117.1.73","article-title":"Predicting survival in patients with recurrent symptomatic malignant pleural effusions: an assessment of the prognostic values of physiologic, morphologic, and quality of life measures of extent of disease","volume":"117","author":"Burrows","year":"2000","journal-title":"Chest"},{"key":"2025110203545358500_ezy258-B127","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken","year":"1982","journal-title":"Am J Clin Oncol"},{"key":"2025110203545358500_ezy258-B128","volume-title":"Evaluation of Chemotherapeutic Agents","author":"Karnofsky","year":"1949"},{"key":"2025110203545358500_ezy258-B129","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1159\/000029240","article-title":"Malignant pleural effusion: prognostic factors for survival and response to chemical pleurodesis in a series of 120 cases","volume":"65","author":"Martinez-Moragon","year":"1998","journal-title":"Respiration"},{"key":"2025110203545358500_ezy258-B130","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/j.rmed.2005.02.022","article-title":"Etiology and prognostic significance of massive pleural effusions","volume":"99","author":"Jim\u00e9nez","year":"2005","journal-title":"Respir Med"},{"key":"2025110203545358500_ezy258-B131","doi-asserted-by":"crossref","first-page":"345","DOI":"10.7326\/0003-4819-108-3-345","article-title":"Pleural fluid pH in malignant effusions. Diagnostic, prognostic, and therapeutic implications","volume":"108","author":"Sahn","year":"1988","journal-title":"Ann Intern Med"},{"key":"2025110203545358500_ezy258-B132","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1097\/JTO.0b013e318208c7c1","article-title":"Thoracoscopic assessment of pleural tumor burden in patients with malignant pleural effusion: prognostic and therapeutic implications","volume":"6","author":"Sakr","year":"2011","journal-title":"J Thorac Oncol"},{"key":"2025110203545358500_ezy258-B133","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1183\/09031936.00069812","article-title":"Survival of lung adenocarcinoma patients with malignant pleural effusion","volume":"41","author":"Wu","year":"2013","journal-title":"Eur Respir J"},{"key":"2025110203545358500_ezy258-B134","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1002\/ijc.22190","article-title":"Usefulness of EGFR mutation screening in pleural fluid to predict the clinical outcome of gefitinib treated patients with lung cancer","volume":"119","author":"Soh","year":"2006","journal-title":"Int J Cancer"},{"key":"2025110203545358500_ezy258-B135","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial","volume":"387","author":"Zalcman","year":"2015","journal-title":"Lancet"},{"key":"2025110203545358500_ezy258-B136","first-page":"1129","article-title":"Levels of vascular endothelial growth factor in serum and pleural fluid are independent predictors of survival in advanced non-small cell lung cancer: results of a prospective study","volume":"35","author":"Gkiozos","year":"2015","journal-title":"Anticancer Res"},{"key":"2025110203545358500_ezy258-B137","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.lungcan.2008.12.007","article-title":"Angiogenetic biomarkers in non-small cell lung cancer with malignant pleural effusion: correlations with patient survival and pleural effusion control","volume":"65","author":"Hsu","year":"2009","journal-title":"Lung Cancer"},{"key":"2025110203545358500_ezy258-B138","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1136\/thorax.55.9.731","article-title":"Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems","volume":"55","author":"Edwards","year":"2000","journal-title":"Thorax"},{"key":"2025110203545358500_ezy258-B139","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1378\/chest.124.5.1916","article-title":"Tumor necrosis correlates with angiogenesis and is a predictor of poor prognosis in malignant mesothelioma","volume":"124","author":"Edwards","year":"2003","journal-title":"Chest"},{"key":"2025110203545358500_ezy258-B140","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1053\/j.gastro.2003.11.010","article-title":"Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis","volume":"126","author":"Rutter","year":"2004","journal-title":"Gastroenterology"},{"key":"2025110203545358500_ezy258-B141","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.cell.2010.01.025","article-title":"Immunity, inflammation, and cancer","volume":"140","author":"Grivennikov","year":"2010","journal-title":"Cell"},{"key":"2025110203545358500_ezy258-B142","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","article-title":"Definition and classification of cancer cachexia: an international consensus","volume":"12","author":"Fearon","year":"2011","journal-title":"Lancet Oncol"},{"key":"2025110203545358500_ezy258-B143","first-page":"516","article-title":"Inflammation in malignant mesothelioma - friend or foe?","volume":"1","author":"Linton","year":"2012","journal-title":"Ann Cardiothorac Surg"},{"key":"2025110203545358500_ezy258-B144","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.ctrv.2012.08.003","article-title":"The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer","volume":"39","author":"McMillan","year":"2013","journal-title":"Cancer Treat Rev"},{"key":"2025110203545358500_ezy258-B145","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1097\/JTO.0b013e31823f45c1","article-title":"Inflammation-based prognostic indices in malignant pleural mesothelioma","volume":"7","author":"Pinato","year":"2012","journal-title":"J Thorac Oncol"},{"key":"2025110203545358500_ezy258-B146","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1038\/sj.bjc.6601242","article-title":"Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer","volume":"89","author":"Forrest","year":"2003","journal-title":"Br J Cancer"},{"key":"2025110203545358500_ezy258-B147","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1097\/JTO.0b013e31816de2b8","article-title":"The impact of additional prognostic factors on survival and their relationship with the anatomical extent of disease expressed by the 6th Edition of the TNM Classification of Malignant Tumors and the proposals for the 7th Edition","volume":"3","author":"Sculier","year":"2008","journal-title":"J Thorac Oncol"},{"key":"2025110203545358500_ezy258-B148","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1200\/JCO.1995.13.5.1221","article-title":"Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. The European Lung Cancer Working Party","volume":"13","author":"Paesmans","year":"1995","journal-title":"J Clin Oncol"},{"key":"2025110203545358500_ezy258-B149","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/sj.bjc.6602702","article-title":"Elevated neutrophil and monocyte counts in peripheral blood are associated with poor survival in patients with metastatic melanoma: a prognostic model","volume":"93","author":"Schmidt","year":"2005","journal-title":"Br J Cancer"},{"key":"2025110203545358500_ezy258-B150","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1038\/sj.bjc.6600768","article-title":"Metastatic renal carcinoma comprehensive prognostic system","volume":"88","author":"Atzpodien","year":"2003","journal-title":"Br J Cancer"},{"key":"2025110203545358500_ezy258-B151","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1177\/172460080401900208","article-title":"Efficacy of cancer chemotherapy in relation to the pretreatment number of lymphocytes in patients with metastatic solid tumors","volume":"19","author":"Lissoni","year":"2003","journal-title":"Int J Biol Markers"},{"key":"2025110203545358500_ezy258-B152","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.jtcvs.2007.10.026","article-title":"Impact of tumor-infiltrating T cells on survival in patients with malignant pleural mesothelioma","volume":"135","author":"Anraku","year":"2008","journal-title":"J Thorac Cardiovasc Surg"},{"key":"2025110203545358500_ezy258-B153","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1007\/s00262-010-0881-6","article-title":"CD8+ tumor-infiltrating lymphocytes predict favorable prognosis in malignant pleural mesothelioma after resection","volume":"59","author":"Yamada","year":"2010","journal-title":"Cancer Immunol Immunother"},{"key":"2025110203545358500_ezy258-B154","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1093\/jnci\/dju124","article-title":"Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis","volume":"106","author":"Templeton","year":"2014","journal-title":"J Natl Canc Inst"},{"key":"2025110203545358500_ezy258-B155","doi-asserted-by":"crossref","first-page":"5805","DOI":"10.1158\/1078-0432.CCR-10-2245","article-title":"High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy","volume":"16","author":"Kao","year":"2010","journal-title":"Clin Cancer Res"},{"key":"2025110203545358500_ezy258-B156","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1136\/thoraxjnl-2014-205285","article-title":"Predicting survival in malignant pleural effusion: development and validation of the LENT prognostic score","volume":"69","author":"Clive","year":"2014","journal-title":"Thorax"},{"key":"2025110203545358500_ezy258-B157","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1038\/bjc.2014.478","article-title":"Factors associated with survival in a large series of patients with malignant pleural mesothelioma in New South Wales","volume":"111","author":"Linton","year":"2014","journal-title":"Br J Cancer"},{"key":"2025110203545358500_ezy258-B158","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1007\/s00262-011-1073-8","article-title":"Chronic inflammation in tumor stroma is an independent predictor of prolonged survival in epithelioid malignant pleural mesothelioma patients","volume":"60","author":"Suzuki","year":"2011","journal-title":"Cancer Immunol Immunother"},{"key":"2025110203545358500_ezy258-B159","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1038\/bjc.2015.62","article-title":"The South West Area Mesothelioma and Pemetrexed trial: a multicentre prospective observational study evaluating novel markers of chemotherapy response and prognostication","volume":"112","author":"Hooper","year":"2015","journal-title":"Br J Cancer"},{"key":"2025110203545358500_ezy258-B160","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1186\/s12885-017-3550-8","article-title":"Prognostic impact of a new score using neutrophil-to-lymphocyte ratios in the serum and malignant pleural effusion in lung cancer patients","volume":"17","author":"Lee","year":"2017","journal-title":"BMC Cancer"},{"key":"2025110203545358500_ezy258-B161","doi-asserted-by":"crossref","first-page":"6839","DOI":"10.1007\/s13277-014-1938-5","article-title":"Serum albumin as a significant prognostic factor in patients with malignant pleural mesothelioma","volume":"35","author":"Yao","year":"2014","journal-title":"Tumour Biol"},{"key":"2025110203545358500_ezy258-B162","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.lungcan.2015.07.014","article-title":"Prognostic significance of the lymphocyte-to-monocyte ratio in patients with malignant pleural mesothelioma","volume":"90","author":"Yamagishi","year":"2015","journal-title":"Lung Cancer"},{"key":"2025110203545358500_ezy258-B163","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1007\/s00432-013-1523-0","article-title":"Prognostic nutritional index predicts outcomes of malignant pleural mesothelioma","volume":"139","author":"Yao","year":"2013","journal-title":"J Cancer Res Clin Oncol"},{"key":"2025110203545358500_ezy258-B164","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.ejcts.2007.09.044","article-title":"Malignant pleural mesothelioma: clinicopathologic and survival characteristics in a consecutive series of 394 patients","volume":"33","author":"Borasio","year":"2008","journal-title":"Eur J Cardiothorac Surg"},{"key":"2025110203545358500_ezy258-B165","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1289\/ehp.11151","article-title":"Asbestos burden predicts survival in pleural mesothelioma","volume":"116","author":"Christensen","year":"2008","journal-title":"Environ Health Perspect"},{"key":"2025110203545358500_ezy258-B166","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.athoracsur.2010.04.110","article-title":"Characteristics of malignant pleural mesothelioma in women","volume":"90","author":"Wolf","year":"2010","journal-title":"Ann Thorac Surg"},{"key":"2025110203545358500_ezy258-B167","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/j.athoracsur.2016.08.063","article-title":"Amount of epithelioid differentiation is a predictor of survival in malignant pleural mesothelioma","volume":"103","author":"Vigneswaran","year":"2017","journal-title":"Ann Thorac Surg"},{"key":"2025110203545358500_ezy258-B168","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/j.jtcvs.2012.09.023","article-title":"Outcome and prognostic factors of pleural mesothelioma after surgical diagnosis and\/or pleurodesis","volume":"145","author":"Baud","year":"2013","journal-title":"J Thorac Cardiovasc Surg"},{"key":"2025110203545358500_ezy258-B169","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1200\/JCO.1998.16.1.145","article-title":"Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience","volume":"16","author":"Curran","year":"1998","journal-title":"J Clin Oncol"},{"key":"2025110203545358500_ezy258-B170","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1016\/j.ejca.2009.04.028","article-title":"A prognostic index for progression-free survival in malignant mesothelioma with application to the design of phase II trials: a combined analysis of 10 EORTC trials","volume":"45","author":"Francart","year":"2009","journal-title":"Eur J Cancer"},{"key":"2025110203545358500_ezy258-B171","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.lungcan.2017.09.012","article-title":"External validation of prognostic indices for overall survival of malignant pleural mesothelioma","volume":"113","author":"Kataoka","journal-title":"Lung Cancer"},{"key":"2025110203545358500_ezy258-B172","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.jtho.2015.10.003","article-title":"Contemporary analysis of prognostic factors in patients with unresectable malignant pleural mesothelioma","volume":"11","author":"Bille","year":"2016","journal-title":"J Thorac Oncol"},{"key":"2025110203545358500_ezy258-B173","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1097\/JTO.0b013e31815608d9","article-title":"Prognostic factors in the treatment of malignant pleural mesothelioma at a large tertiary referral center","volume":"2","author":"Flores","year":"2007","journal-title":"J Thorac Oncol"},{"key":"2025110203545358500_ezy258-B174","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.canep.2013.12.002","article-title":"Malignant pleural mesothelioma incidence and survival in the Republic of Ireland 1994\u20132009","volume":"38","author":"Jennings","year":"2014","journal-title":"Cancer Epidemiol"},{"key":"2025110203545358500_ezy258-B175","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/ijc.23874","article-title":"Survival of pleural malignant mesothelioma in Italy: a population-based study","volume":"124","author":"Montanaro","year":"2009","journal-title":"Int J Cancer"},{"key":"2025110203545358500_ezy258-B176","doi-asserted-by":"crossref","first-page":"e0145039","DOI":"10.1371\/journal.pone.0145039","article-title":"Determinants of survival in malignant pleural mesothelioma: a surveillance, epidemiology, and end results (SEER) study of 14,228 patients","volume":"10","author":"Taioli","year":"2015","journal-title":"PLoS One"},{"key":"2025110203545358500_ezy258-B177","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.athoracsur.2014.11.050","article-title":"Persistent lung expansion after pleural talc poudrage in non-surgically resected malignant pleural mesothelioma","volume":"99","author":"Rena","year":"2015","journal-title":"Ann Thorac Surg"},{"key":"2025110203545358500_ezy258-B178","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1759-7714.2010.00033.x","article-title":"Malignant pleural mesothelioma: a retrospective analysis of clinicopathological and survival data","volume":"2","author":"Adel","year":"2011","journal-title":"Thorac Cancer"},{"key":"2025110203545358500_ezy258-B179","first-page":"2073","article-title":"Survival in good performance malignant pleural mesothelioma patients; prognostic factors and predictors of response","volume":"18","author":"Rahouma","year":"2017","journal-title":"Asian Pac J Cancer Prev"},{"key":"2025110203545358500_ezy258-B180","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ijsu.2017.10.034","article-title":"The revised staging system for malignant pleural mesothelioma based on surveillance, epidemiology, and end results database","volume":"48","author":"Wang","year":"2017","journal-title":"Int J Surg"},{"key":"2025110203545358500_ezy258-B181","doi-asserted-by":"crossref","first-page":"114","DOI":"10.4149\/neo_2017_114","article-title":"Elevated aspartate aminotransferase and monocyte counts predict unfavorable prognosis in patients with malignant pleural mesothelioma","volume":"64","author":"Zhang","year":"2017","journal-title":"Neoplasma"},{"key":"2025110203545358500_ezy258-B182","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1093\/jjco\/hyv039","article-title":"A new prognostic index for overall survival in malignant pleural mesothelioma: the rPHS (regimen, PS, histology or stage) index","volume":"45","author":"Kataoka","year":"2015","journal-title":"Jpn J Clin Oncol"},{"key":"2025110203545358500_ezy258-B183","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1378\/chest.113.3.723","article-title":"Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B","volume":"113","author":"Herndon","year":"1998","journal-title":"Chest"},{"key":"2025110203545358500_ezy258-B184","doi-asserted-by":"crossref","first-page":"5770","DOI":"10.1200\/JCO.2007.12.5294","article-title":"Symptoms and patient-reported well-being: do they predict survival in malignant pleural mesothelioma? A prognostic factor analysis of EORTC-NCIC 08983: randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma","volume":"25","author":"Bottomley","year":"2007","journal-title":"J Clin Oncol"},{"key":"2025110203545358500_ezy258-B185","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1158\/1078-0432.CCR-10-1929","article-title":"Serum soluble mesothelin concentrations in malignant pleural mesothelioma: relationship to tumor volume, clinical stage and changes in tumor burden","volume":"17","author":"Creaney","year":"2011","journal-title":"Clin Cancer Res"},{"key":"2025110203545358500_ezy258-B186","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/bjc.2017.22","article-title":"Prognostication and monitoring of mesothelioma using biomarkers: a systematic review","volume":"116","author":"Arnold","year":"2017","journal-title":"Br J Cancer"},{"key":"2025110203545358500_ezy258-B187","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1097\/JTO.0b013e3182272294","article-title":"Soluble mesothelin, megakaryocyte potentiating factor, and osteopontin as markers of patient response and outcome in mesothelioma","volume":"6","author":"Hollevoet","year":"2011","journal-title":"J Thorac Oncol"},{"key":"2025110203545358500_ezy258-B188","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1200\/JCO.2005.07.050","article-title":"Statistical validation of the EORTC prognostic model for malignant pleural mesothelioma based on three consecutive phase II trials","volume":"23","author":"Fennell","year":"2005","journal-title":"J Clin Oncol"},{"key":"2025110203545358500_ezy258-B189","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.21037\/jtd.2016.07.55","article-title":"Validation of EORTC and CALGB prognostic models in surgical patients submitted to diagnostic, palliative or curative surgery for malignant pleural mesothelioma","volume":"8","author":"Sandri","year":"2016","journal-title":"J Thorac Dis"},{"key":"2025110203545358500_ezy258-B190","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1038\/bjc.2013.504","article-title":"Existing models, but not neutrophil-to-lymphocyte ratio, are prognostic in malignant mesothelioma","volume":"109","author":"Meniawy","year":"2013","journal-title":"Br J Cancer"},{"key":"2025110203545358500_ezy258-B191","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1007\/s00268-017-4424-6","article-title":"A nomogram to predict prognosis in malignant pleural mesothelioma","volume":"42","author":"Wang","journal-title":"World J Surg 2017;"},{"key":"2025110203545358500_ezy258-B192","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.jtho.2015.12.108","article-title":"A novel clinical prediction model for prognosis in malignant pleural mesothelioma using decision tree analysis","volume":"11","author":"Brims","year":"2016","journal-title":"J Thorac Oncol"},{"key":"2025110203545358500_ezy258-B193","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1097\/JTO.0b013e31817c606a","article-title":"Clinical outcome of chemoradiation therapy in patients with limited-disease small cell lung cancer with ipsilateral pleural effusion","volume":"3","author":"Niho","year":"2008","journal-title":"J Thorac Oncol"},{"key":"2025110203545358500_ezy258-B194","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/0959-8049(92)90459-F","article-title":"Increased myelosuppression during cytostatic treatment and pleural effusion in patients with small cell lung cancer","volume":"28","author":"Herrstedt","year":"1992","journal-title":"Eur J Cancer"},{"key":"2025110203545358500_ezy258-B195","volume-title":"Pleural diseases","author":"Light","year":"2007"},{"key":"2025110203545358500_ezy258-B196","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/j.1600-0463.2008.00005.x","article-title":"Human herpes virus 8-unrelated primary effusion lymphoma-like lymphoma: report of a rare case and review of the literature","volume":"117","author":"Adiguzel","year":"2009","journal-title":"APMIS"},{"key":"2025110203545358500_ezy258-B197","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1089\/108729104322802498","article-title":"Failure to eradicate AIDS-associated primary effusion lymphoma with high-dose chemotherapy and autologous stem cell reinfusion: case report and literature review","volume":"18","author":"Waddington","year":"2004","journal-title":"AIDS Patient Care STDS"},{"key":"2025110203545358500_ezy258-B198","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.1002\/cncr.10552","article-title":"The role of local radiation therapy for mediastinal disease in adults with T-cell lymphoblastic lymphoma","volume":"94","author":"Dabaja","year":"2002","journal-title":"Cancer"},{"key":"2025110203545358500_ezy258-B199","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1378\/chest.119.2.340","article-title":"Combination chemotherapy in patients with malignant pleural effusions from non-small cell lung cancer: cisplatin, ifosfamide, and irinotecan with recombinant human granulocyte colony-stimulating factor support","volume":"119","author":"Fujita","year":"2001","journal-title":"Chest"},{"key":"2025110203545358500_ezy258-B200","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s00280-012-2026-4","article-title":"Bevacizumab plus chemotherapy for advanced non-squamous non-small-cell lung cancer with malignant pleural effusion","volume":"71","author":"Kitamura","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"key":"2025110203545358500_ezy258-B201","doi-asserted-by":"crossref","first-page":"415","DOI":"10.3892\/mco.2014.457","article-title":"Response to bevacizumab combination chemotherapy of malignant pleural effusions associated with non-squamous non-small-cell lung cancer","volume":"3","author":"Masago","year":"2015","journal-title":"Mol Clin Oncol"},{"key":"2025110203545358500_ezy258-B202","first-page":"588","article-title":"Effective treatment of a patient with stage IV ovarian cancer: a case report","volume":"15","author":"Huang","year":"2018","journal-title":"Oncol Lett"},{"key":"2025110203545358500_ezy258-B203","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1080\/1061186X.2016.1200590","article-title":"Sequential treatment strategy for malignant pleural effusion in non-small cell lung cancer with the activated epithelial grow factor receptor mutation","volume":"25","author":"Lin","year":"2017","journal-title":"J Drug Target"},{"key":"2025110203545358500_ezy258-B204","doi-asserted-by":"crossref","first-page":"62648","DOI":"10.18632\/oncotarget.16061","article-title":"Addition of bevacizumab for malignant pleural effusion as the manifestation of acquired EGFR-TKI resistance in NSCLC patients","volume":"8","author":"Jiang","year":"2017","journal-title":"Oncotarget"},{"key":"2025110203545358500_ezy258-B205","doi-asserted-by":"crossref","first-page":"48521","DOI":"10.18632\/oncotarget.17952","article-title":"Bevacizumab for ramucirumab refractory malignant pleural effusion in non-small cell lung cancer: a case report and review of the literature","volume":"8","author":"Mori","year":"2017","journal-title":"Oncotarget"},{"key":"2025110203545358500_ezy258-B206","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/CJI.0b013e318195b5bb","article-title":"Treatment of malignant pleural effusion with the trifunctional antibody catumaxomab (removab) (anti-EpCAMxanti-CD3): results of a phase 1\/2 study","volume":"32","author":"Sebastian","year":"2009","journal-title":"J Immunother"},{"key":"2025110203545358500_ezy258-B207","first-page":"273","article-title":"Catumaxomab, a rat\/murine hybrid trifunctional bispecific monoclonal antibody for the treatment of cancer","volume":"10","author":"Shen","year":"2008","journal-title":"Curr Opin Mol Ther"},{"key":"2025110203545358500_ezy258-B208","doi-asserted-by":"crossref","first-page":"e5392","DOI":"10.1097\/MD.0000000000005392","article-title":"Combination use of paclitaxel and avastin enhances treatment effect for the NSCLC patients with malignant pleural effusion","volume":"95","author":"Qi","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"2025110203545358500_ezy258-B209","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.3892\/or.2013.2349","article-title":"Intrapleural combination therapy with bevacizumab and cisplatin for non-small cell lung cancer-mediated malignant pleural effusion","volume":"29","author":"Du","year":"2013","journal-title":"Oncol Rep"},{"key":"2025110203545358500_ezy258-B210","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1007\/s12032-013-0676-7","article-title":"Phase2 study of bevacizumab with carboplatin-paclitaxel for non-small cell lung cancer with malignant pleural effusion","volume":"30","author":"Tamiya","year":"2013","journal-title":"Med Oncol"},{"key":"2025110203545358500_ezy258-B211","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1378\/chest.67.5.536","article-title":"Efficacy of pleural needle biopsy and pleural fluid cytopathology in the diagnosis of malignant neoplasm involving the pleura","volume":"67","author":"Salyer","year":"1975","journal-title":"Chest"},{"key":"2025110203545358500_ezy258-B212","first-page":"320","article-title":"Diagnostic efficacy of pleural biopsy as compared with that of pleural fluid examination","volume":"4","author":"Nance","year":"1991","journal-title":"Mod Pathol"},{"key":"2025110203545358500_ezy258-B213","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/S0025-6196(12)60212-2","article-title":"Comparison of needle biopsy with cytologic analysis for the evaluation of pleural effusion: analysis of 414 cases","volume":"60","author":"Prakash","year":"1985","journal-title":"Mayo Clin Proc"},{"key":"2025110203545358500_ezy258-B214","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1111\/crj.12619","article-title":"Positive pleural cytology is an indicator for visceral pleural invasion in metastatic pleural effusions","volume":"12","author":"Froudarakis","year":"2018","journal-title":"Clin Respir J"},{"key":"2025110203545358500_ezy258-B215","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1378\/chest.111.1.106","article-title":"The role of cytologic evaluation of pleural fluid in the diagnosis of malignant mesothelioma","volume":"111","author":"Renshaw","year":"1997","journal-title":"Chest"},{"key":"2025110203545358500_ezy258-B216","first-page":"ii4","article-title":"Investigation of a unilateral pleural effusion in adults: British Thoracic Society Pleural Disease Guideline 2010","volume":"65: Suppl. 2","author":"Hooper","year":"2010","journal-title":"Thorax"},{"key":"2025110203545358500_ezy258-B217","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1136\/jclinpath-2012-201303","article-title":"Challenges and controversies in the diagnosis of mesothelioma: part 1. Cytology-only diagnosis, biopsies, immunohistochemistry, discrimination between mesothelioma and reactive mesothelial hyperplasia, and biomarkers","volume":"66","author":"Henderson","year":"2013","journal-title":"J Clin Pathol"},{"key":"2025110203545358500_ezy258-B218","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1097\/PAT.0b013e32835bc848","article-title":"A diagnosis of malignant pleural mesothelioma can be made by effusion cytology: results of a 20 year audit","volume":"45","author":"Segal","year":"2013","journal-title":"Pathology"},{"key":"2025110203545358500_ezy258-B219","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/cncy.21518","article-title":"The role of liquid-based cytology and ancillary techniques in pleural and pericardic effusions: an institutional experience","volume":"123","author":"Rossi","year":"2015","journal-title":"Cancer Cytopathol"},{"issue":"5 Suppl","key":"2025110203545358500_ezy258-B220","doi-asserted-by":"crossref","first-page":"e142S","DOI":"10.1378\/chest.12-2353","article-title":"Establishing the diagnosis of lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines","volume":"143","author":"Rivera","year":"2013","journal-title":"Chest"},{"key":"2025110203545358500_ezy258-B221","first-page":"665","article-title":"The value of multiple fluid specimens in the cytological diagnosis of malignancy","volume":"7","author":"Garcia","year":"1994","journal-title":"Mod Pathol"},{"key":"2025110203545358500_ezy258-B222","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1002\/dc.21303","article-title":"The sensitivity of cytologic evaluation of pleural fluid in the diagnosis of malignant mesothelioma","volume":"38","author":"Rakha","year":"2010","journal-title":"Diagn Cytopathol"},{"key":"2025110203545358500_ezy258-B223","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1097\/JTO.0b013e31823e0667","article-title":"Pleural fluid cytological yield and visceral pleural invasion in patients with epithelioid malignant pleural mesothelioma","volume":"7","author":"Pinelli","year":"2012","journal-title":"J Thorac Oncol"},{"key":"2025110203545358500_ezy258-B224","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1378\/chest.08-2002","article-title":"A prospective study of the volume of pleural fluid required for accurate diagnosis of malignant pleural effusion","volume":"135","author":"Abouzgheib","year":"2009","journal-title":"Chest"},{"key":"2025110203545358500_ezy258-B225","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/j.1365-2303.2010.00786.x","article-title":"An investigation of adequate volume for the diagnosis of malignancy in pleural fluids","volume":"22","author":"Thomas","year":"2011","journal-title":"Cytopathology"},{"key":"2025110203545358500_ezy258-B226","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1002\/cncy.21452","article-title":"A minimum fluid volume of 75 mL is needed to ensure adequacy in a pleural effusion: a retrospective analysis of 2540 cases","volume":"122","author":"Rooper","year":"2014","journal-title":"Cancer Cytopathol"},{"key":"2025110203545358500_ezy258-B227","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1378\/chest.09-0641","article-title":"Prospective study to determine the volume of pleural fluid required to diagnose malignancy","volume":"137","author":"Swiderek","year":"2010","journal-title":"Chest"},{"key":"2025110203545358500_ezy258-B228","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.rce.2016.11.004","article-title":"Examination of cytological smears and cell blocks of pleural fluid: complementary diagnostic value for malignant effusions","volume":"217","author":"Porcel","year":"2017","journal-title":"Rev Clin Esp"},{"key":"2025110203545358500_ezy258-B229","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1093\/ajcp\/70.6.855","article-title":"Cytology of serous effusions: an investigation into the usefulness of cell blocks versus smears","volume":"70","author":"Dekker","year":"1978","journal-title":"Am J Clin Pathol"},{"key":"2025110203545358500_ezy258-B230","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jtho.2015.11.005","article-title":"The 2015 World Health Organization Classification of Tumors of the Pleura: advances since the 2004 classification","volume":"11","author":"Galateau-Salle","year":"2016","journal-title":"J Thorac Oncol"},{"key":"2025110203545358500_ezy258-B231","doi-asserted-by":"crossref","first-page":"647","DOI":"10.5858\/arpa.2012-0214-OA","article-title":"Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group","volume":"137","author":"Husain","year":"2013","journal-title":"Arch Pathol Lab Med"},{"key":"2025110203545358500_ezy258-B232","doi-asserted-by":"crossref","first-page":"89","DOI":"10.5858\/arpa.2017-0124-RA","article-title":"Guidelines for pathologic diagnosis of malignant mesothelioma: 2017 update of the consensus statement from the International Mesothelioma Interest Group","volume":"142","author":"Husain","year":"2017","journal-title":"Arch Pathol Lab Med"},{"key":"2025110203545358500_ezy258-B233","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.rmed.2015.05.014","article-title":"Pleural neoplastic pathology","volume":"109","author":"Karpathiou","year":"2015","journal-title":"Respir Med"},{"key":"2025110203545358500_ezy258-B234","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1159\/000468545","article-title":"Diagnostic accuracy of combinations of tumor markers for malignant pleural effusion: an updated meta-analysis","volume":"94","author":"Yang","year":"2017","journal-title":"Respiration"},{"key":"2025110203545358500_ezy258-B235","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/dc.2840030202","article-title":"A morphologic, immunologic, and cytometric approach to the classification of non-Hodgkin's lymphoma in effusions","volume":"3","author":"Katz","year":"1987","journal-title":"Diagn Cytopathol"},{"key":"2025110203545358500_ezy258-B236","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1002\/(SICI)1097-0339(199905)20:5<278::AID-DC6>3.0.CO;2-W","article-title":"Immunophenotypic analysis of non-Hodgkin's lymphomas in cytologic specimens: a correlative study of immunocytochemical and flow cytometric techniques","volume":"20","author":"Simsir","year":"1999","journal-title":"Diagn Cytopathol"},{"key":"2025110203545358500_ezy258-B237","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1309\/AJCP4HIFSHMO9WTK","article-title":"A simplified flow cytometric immunophenotyping procedure for the diagnosis of effusions caused by epithelial malignancies","volume":"139","author":"Pillai","year":"2013","journal-title":"Am J Clin Pathol"},{"key":"2025110203545358500_ezy258-B238","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1309\/M877-QABM-D9GB-FJAX","article-title":"Detection of malignant epithelial cells in effusions using flow cytometric immunophenotyping: an analysis of 92 cases","volume":"118","author":"Davidson","year":"2002","journal-title":"Am J Clin Pathol"},{"key":"2025110203545358500_ezy258-B239","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/cyto.b.21258","article-title":"Screening of carcinoma metastasis by flow cytometry: a study of 238 cases","volume":"90","author":"Acosta","year":"2016","journal-title":"Cytometry B Clin Cytom"},{"key":"2025110203545358500_ezy258-B240","doi-asserted-by":"crossref","first-page":"212ra163","DOI":"10.1126\/scitranslmed.3006559","article-title":"Quantitative diagnosis of malignant pleural effusions by single-cell mechanophenotyping","volume":"5","author":"Tse","year":"2013","journal-title":"Sci Transl Med"},{"key":"2025110203545358500_ezy258-B241","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1097\/PAS.0000000000000825","article-title":"GATA3 immunohistochemistry for distinguishing sarcomatoid and desmoplastic mesothelioma from sarcomatoid carcinoma of the lung","volume":"41","author":"Berg","year":"2017","journal-title":"Am J Surg Pathol"},{"key":"2025110203545358500_ezy258-B242","doi-asserted-by":"crossref","first-page":"318","DOI":"10.5858\/arpa.2015-0240-SA","article-title":"New markers for separating benign from malignant mesothelial proliferations: are we there yet?","volume":"140","author":"Churg","year":"2016","journal-title":"Arch Pathol Lab Med"},{"key":"2025110203545358500_ezy258-B243","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1097\/PAS.0000000000000529","article-title":"Utility of BAP1 immunohistochemistry and p16 (CDKN2A) FISH in the diagnosis of malignant mesothelioma in effusion cytology specimens","volume":"40","author":"Hwang","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"2025110203545358500_ezy258-B244","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/modpathol.2015.65","article-title":"BAP1 (BRCA1-associated protein 1) is a highly specific marker for differentiating mesothelioma from reactive mesothelial proliferations","volume":"28","author":"Cigognetti","year":"2015","journal-title":"Mod Pathol"},{"key":"2025110203545358500_ezy258-B245","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1002\/dc.23490","article-title":"Cytologic differential diagnosis of malignant mesothelioma and reactive mesothelial cells with FISH analysis of p16","volume":"44","author":"Hiroshima","year":"2016","journal-title":"Diagn Cytopathol"},{"key":"2025110203545358500_ezy258-B246","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/cncy.21342","article-title":"The diagnosis of malignant mesothelioma in effusion cytology: a reappraisal and results of a multi-institution survey","volume":"121","author":"Paintal","year":"2013","journal-title":"Cancer Cytopathol"},{"key":"2025110203545358500_ezy258-B247","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1097\/PAS.0000000000000696","article-title":"A histomorphologic grading system that predicts overall survival in diffuse malignant peritoneal mesothelioma with epithelioid subtype","volume":"40","author":"Valente","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"2025110203545358500_ezy258-B248","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s00428-017-2109-z","article-title":"Histopathologic features predict survival in diffuse pleural malignant mesothelioma on pleural biopsies","volume":"470","author":"Habougit","year":"2017","journal-title":"Virchows Arch"},{"key":"2025110203545358500_ezy258-B249","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/modpathol.2011.146","article-title":"A nuclear grading system is a strong predictor of survival in epitheloid diffuse malignant pleural mesothelioma","volume":"25","author":"Kadota","year":"2012","journal-title":"Mod Pathol"},{"key":"2025110203545358500_ezy258-B250","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/bjc.2015.9","article-title":"Ki67 index is an independent prognostic factor in epithelioid but not in non-epithelioid malignant pleural mesothelioma: a multicenter study","volume":"112","author":"Ghanim","year":"2015","journal-title":"Br J Cancer"},{"key":"2025110203545358500_ezy258-B251","article-title":"Adequacy of malignant pleural effusion for epidermal growth factor receptor mutation analysis using the pyrosequencing method","volume":"2","author":"Hatoum","year":"2015","journal-title":"Pleura (Thousand Oaks)"},{"key":"2025110203545358500_ezy258-B252","first-page":"1169","article-title":"Molecular profiling of malignant pleural effusion in metastatic non-small-cell lung carcinoma the effect of preanalytical factors","volume":"14","author":"Carter","year":"2017","journal-title":"Ann Am Thorac Soc"},{"key":"2025110203545358500_ezy258-B253","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1515\/cclm-2016-0851","article-title":"Assessment of real-time PCR method for detection of EGFR mutation using both supernatant and cell pellet of malignant pleural effusion samples from non-small-cell lung cancer patients","volume":"55","author":"Shin","year":"2017","journal-title":"Clin Chem Lab Med"},{"key":"2025110203545358500_ezy258-B254","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1073\/pnas.1612229114","article-title":"High-throughput screening of rare metabolically active tumor cells in pleural effusion and peripheral blood of lung cancer patients","volume":"114","author":"Tang","year":"2017","journal-title":"Proc Natl Acad Sci USA"},{"issue":"Suppl. 2","key":"2025110203545358500_ezy258-B255","first-page":"ii54","article-title":"Local anaesthetic thoracoscopy: British Thoracic Society Pleural Disease Guideline 2010","volume":"65","author":"Rahman","year":"2010","journal-title":"Thorax"},{"key":"2025110203545358500_ezy258-B256","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1097\/MCP.0000000000000258","article-title":"Pleural biopsies in undiagnosed pleural effusions; Abrams vs image-guided vs thoracoscopic biopsies","volume":"22","author":"Bibby","year":"2016","journal-title":"Curr Opin Pulm Med"},{"key":"2025110203545358500_ezy258-B257","doi-asserted-by":"crossref","first-page":"e0167186","DOI":"10.1371\/journal.pone.0167186","article-title":"Diagnostic utility of pleural fluid cell block versus pleural biopsy collected by flex-rigid pleuroscopy for malignant pleural disease: a single center retrospective analysis","volume":"11","author":"Miyoshi","year":"2016","journal-title":"PLoS One"},{"key":"2025110203545358500_ezy258-B258","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.ejcts.2010.01.057","article-title":"Outcome of patients with nonspecific pleuritis\/fibrosis on thoracoscopic pleural biopsies","volume":"38","author":"Davies","year":"2010","journal-title":"Eur J Cardiothorac Surg"},{"key":"2025110203545358500_ezy258-B259","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.arbres.2014.09.016","article-title":"Long-term outcome of patients with undiagnosed pleural effusion","volume":"51","author":"Gunluoglu","year":"2015","journal-title":"Arch Bronconeumol"},{"key":"2025110203545358500_ezy258-B260","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1159\/000083404","article-title":"Does \u2018idiopathic pleuritis\u2019 exist? Natural history of non-specific pleuritis diagnosed after thoracoscopy","volume":"72","author":"Venekamp","year":"2005","journal-title":"Respiration"},{"key":"2025110203545358500_ezy258-B261","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/01.lab.0000131024.20254.81","article-title":"The long-term follow-up of exudative pleural effusion after nondiagnostic thoracoscopy","volume":"11","author":"Janssen","year":"2004","journal-title":"J Bronchol"},{"key":"2025110203545358500_ezy258-B262","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.rmed.2017.01.005","article-title":"Long-term outcome of patients with nonspecific pleurisy at medical thoracoscopy","volume":"124","author":"Yang","year":"2017","journal-title":"Respir Med"},{"key":"2025110203545358500_ezy258-B263","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/nrclinonc.2017.14","article-title":"Integrating liquid biopsies into the management of cancer","volume":"14","author":"Siravegna","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"2025110203545358500_ezy258-B264","first-page":"635","article-title":"miR-130A as a diagnostic marker to differentiate malignant mesothelioma from lung adenocarcinoma in pleural effusion cytology","volume":"125","author":"Cappellesso","year":"2017","journal-title":"Cancer"},{"key":"2025110203545358500_ezy258-B265","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1001\/jamaoncol.2014.257","article-title":"Association of EGFR L858R mutation in circulating free DNA with survival in the EURTAC trial","volume":"1","author":"Karachaliou","year":"2015","journal-title":"JAMA Oncol"},{"key":"2025110203545358500_ezy258-B266","doi-asserted-by":"crossref","first-page":"3196","DOI":"10.1158\/1078-0432.CCR-14-2594","article-title":"Detection and dynamic changes of EGFR mutations from circulating tumor DNA as a predictor of survival outcomes in NSCLC patients treated with first-line intercalated erlotinib and chemotherapy","volume":"21","author":"Mok","year":"2015","journal-title":"Clin Cancer Res"},{"key":"2025110203545358500_ezy258-B267","doi-asserted-by":"crossref","first-page":"3375","DOI":"10.1200\/JCO.2016.66.7162","article-title":"Association between plasma genotyping and outcomes of treatment with osimertinib (AZD9291) in advanced non-small-cell lung cancer","volume":"34","author":"Oxnard","year":"2016","journal-title":"J Clin Oncol"},{"key":"2025110203545358500_ezy258-B268","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1001\/jamaoncol.2016.0173","article-title":"Prospective validation of rapid plasma genotyping for the detection of EGFR and KRAS mutations in advanced lung cancer","volume":"2","author":"Sacher","year":"2016","journal-title":"JAMA Oncol"},{"key":"2025110203545358500_ezy258-B269","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.lungcan.2013.09.017","article-title":"The degree of microRNA-34b\/c methylation in serum-circulating DNA is associated with malignant pleural mesothelioma","volume":"82","author":"Muraoka","year":"2013","journal-title":"Lung Cancer"},{"key":"2025110203545358500_ezy258-B270","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.lungcan.2015.09.021","article-title":"Combined circulating epigenetic markers to improve mesothelin performance in the diagnosis of malignant mesothelioma","volume":"90","author":"Santarelli","year":"2015","journal-title":"Lung Cancer"},{"key":"2025110203545358500_ezy258-B271","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1097\/JTO.0b013e3182572e83","article-title":"Increased circulating miR-625\u20133p: a potential biomarker for patients with malignant pleural mesothelioma","volume":"7","author":"Kirschner","year":"2012","journal-title":"J Thorac Oncol"}],"container-title":["European Journal of Cardio-Thoracic Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ejcts\/article-pdf\/55\/1\/116\/64103099\/ejcts_55_1_116.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ejcts\/article-pdf\/55\/1\/116\/64103099\/ejcts_55_1_116.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T08:55:23Z","timestamp":1762073723000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ejcts\/article\/55\/1\/116\/5060018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,27]]},"references-count":271,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ejcts\/ezy258","relation":{},"ISSN":["1010-7940","1873-734X"],"issn-type":[{"value":"1010-7940","type":"print"},{"value":"1873-734X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,1]]},"published":{"date-parts":[[2018,7,27]]}}}